Featured News
A Commitment to Incubating Promising Drug Developers
Advanced therapy developers form part of our inaugural Incubator Program cohort
The Charles River Incubator Program (CIP) aims to expedite the development of life-changing therapies for patients in need by offering early-stage biotechnology pioneers access to extensive scientific and commercial expertise and a wide ecosystem of discovery, development, and manufacturing capabilities.
The initial cohort of six companies includes four advanced therapy developers, which will benefit from tailored mentorship, consultative regulatory and quality expertise, fit-for-purpose training initiatives, and preferential access to our global network of facilities.
Want to be Part of the Next CIP Cohort?
Complete the form to take the first step and a member of our team will be in touch to discuss additional information required to support your application.
Apply Today
Gordian Bio
Developing novel therapeutics for chronic conditions leveraging an innovative screening platform that measures in vivo efficacy and safety of thousands of novel gene targets simultaneously, in individual animal models of disease.
"Our in vivo screening technology has rapidly identified multiple development candidates in osteoarthritis and heart failure, and is powering partnerships across obesity, lung fibrosis, and cirrhosis," said Dr. Francisco LePort, Co-Founder and Chief Executive Officer, Gordian Bio. "We are excited to join CIP as these programs advance toward the clinic."
NVI Therapeutics
A company committed to empowering cell and gene therapy with non-viral gene insertion technology.
"By joining the CIP, NVI Therapeutics aims to accelerate the development of our non-viral gene insertion platform through strategic business development support and expert mentorship," said Chih-Wen Ni, Ph.D., Founder and CEO, NVI Therapeutics, Inc. "Access to Charles River's extensive network will be invaluable and collaboration with their world-class team will streamline our preclinical studies and help fast-track our path to the clinic."
Shortlisted at our Cell & Gene Therapy Summit in San Francisco on March 4, 2025, the founders of NVI Therapeutics and Adjuva Bio presented their companies to potential investors in the Investment Track.
Adjuva Bio
Adjuva Bio is developing precision-engineered cell therapies for chronic inflammatory diseases; its LogiCAR platform aims to enable programmable cell therapies designed to treat conditions with high unmet need and limited treatment options, such as endometriosis and fibrosis.
"At Adjuva Bio, we're expanding the reach of cell therapy to tackle chronic diseases that have been ignored for too long," said Bishwas Shrestha, Ph.D., Co-Founder, Adjuva Bio.
Cell & Gene Therapy Summit 2026
Join global leaders in cell and gene therapy on March 26 at the CGT Summit in Boston to explore the latest innovations and critical challenges shaping the future of advanced therapies.
Save Your Seat
NanoPalm
Developing in vivo therapies for genetic diseases with an advanced lipid nanoparticle (LNP) manufacturing process designed by NanoPalm's artificial intelligence (AI) platform.
"Being selected for the Charles River Incubator Program marks a significant milestone for NanoPalm as we continue our mission to develop next-generation, accessible gene therapies," said Dr. Ali Alhasan, Founder and CEO of NanoPalm. "This collaboration will accelerate our ability to translate groundbreaking research into real-world clinical solutions and reflects how Saudi Arabia is transforming the biotech ecosystem to align with Vision 2030."
As part of a commitment to developing a robust biotechnology ecosystem in the Middle East, we joined forces with Lafana Holding to shortlist and select NanoPalm for inclusion in the first CIP cohort, helping to grow the life sciences industry in Saudi Arabia.
"We were incredibly impressed with the caliber of applicants for the CIP and are proud of the group chosen to participate in this first round," said Kerstin Dolph, Corporate Senior Vice President of Global Manufacturing, Charles River. "The goal of the CIP is to form a strong foundation for commercial viability as our participants support the development of life-saving therapeutics."
For more information on our plasmid DNA, viral vector, and cell therapy development and manufacturing platforms and services, plus integrated testing capabilities, please visit Cell and Gene Therapy CDMO Solutions.